Our findings suggest that identification of agents which increase hepatic TOMM40 expression, and in doing so, maintain mitochondrial function and MERCs, could provide new therapeutic opportunities for MASLD, as well as other conditions such as Alzheimer’s disease in which mitochondrial pathology plays a role. The gene discussed is TOMM40; the disease is metabolic dysfunction-associated steatotic liver disease.